selected scholarly activity
-
conferences
- The Association Between Intradialytic Symptom Clusters and Recovery Time in Patients Undergoing Maintenance Hemodialysis: An Exploratory Analysis. Canadian Journal of Kidney Health and Disease. 2024
- LOCAL ADVERSE REACTIONS DECREASED OVER TIME DURING IGHY TREATMENT IN PATIENTS WITH PIDD. Annals of Allergy, Asthma and Immunology. S97-S98. 2016
- MECHANISM OF HYALURONIDASE-FACILITATED SCIG ALLOWING INVESTIGATIONS IN NEUROMUSCULAR DISORDERS. Journal of the Peripheral Nervous System. 203-203. 2016
- MAJOR BLEEDING IN MEDICAL-SURGICAL CRITICALLY ILL PATIENTS IS ASSOCIATED WITH INCREASED USE OF BLOOD PRODUCTS, LONGER HOSPITAL STAY AND HIGHER MORTALITY. Critical Care Medicine. U39-U40. 2012
- Adjudicating Bleeding Outcomes in a Large Thromboprophylaxis Trial in Critical Illness. Blood. 974-974. 2009
- Attributable morbidity and mortality of DVT. Critical Care Medicine. A174-A174. 2007
- Anti-Xa levels and renal function: Analysis of the first 32 patients in the tinzaparin in renal insufficiency for venous thromboembolism study. Blood. 266A-266A. 2005
- Cardiac disease, vascular disease and medication use in patients with chronic renal insufficiency referred to nephrologists.. Journal of the American Society of Nephrology. 792A-792A. 2003
- Hemoglobin variability in hemodialysis patients: Impact of an anemia management protocol.. Journal of the American Society of Nephrology. 854A-854A. 2003
- Metabolic complications in patients with chronic renal insufficiency referred to nephrologists.. Journal of the American Society of Nephrology. 791A-791A. 2003
- CALCULATED CREATININE CLEARANCE IN ICU PATIENTS RECEIVING LOW MOLECULAR WEIGHT HEPARIN: AN INTER-RATER RELIABILITY STUDY. Critical Care Medicine. A154-A154. 2002
- RELATIONSHIP BETWEEN TROUGH ANTI-XA LEVELS AND CALCULATED CREATININE CLEARANCE IN ICU PATIENTS RECEIVING LOW MOLECULAR WEIGHT HEPARIN. Critical Care Medicine. A154-A154. 2002
- Benefit of continuous dialysis in subgroups of acutely ill patients: A retrospective analysis. Journal of the American Society of Nephrology. 445A-445A. 2002
- Renin-angiotensin system (RAS) genetic polymorphisms and left ventricular hypertrophy (LVH).. Journal of the American Society of Nephrology. A0658-A0658. 1997
- The role of heparin-induced thrombocytopenia (HIT) in the thrombocytopenia and thrombotic events in chronic hemodialysis (HD) patients.. Journal of the American Society of Nephrology. A1150-A1150. 1997
-
journal articles
- Pyoderma Gangrenosum After Insertion of a Hemodialysis Catheter: Koebner Phenomenon, Systemic Inflammatory Response Syndrome, and a Delay in Diagnosis. Canadian Journal of Kidney Health and Disease. 9:205435812211206-205435812211206. 2022
- Comparing Renal Replacement Therapy Modalities in Critically Ill Patients With Acute Kidney Injury: A Systematic Review and Network Meta-Analysis. Critical Care Explorations. 3:e0399-e0399. 2021
- Nephrologist Views Regarding Cannabinoid Use in Advanced Chronic Kidney Disease and Dialysis: A Survey. Journal of Pain and Symptom Management. 61:237-245.e2. 2021
- The DIalysis Symptom COntrol-Restless Legs Syndrome (DISCO-RLS) Trial: A Protocol for a Randomized, Crossover, Placebo-Controlled Blinded Trial. Canadian Journal of Kidney Health and Disease. 7:205435812096895-205435812096895. 2020
- Screening questions for the diagnosis of restless legs syndrome in hemodialysis. CKJ: Clinical Kidney Journal. 12:559-563. 2019
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. The Lancet. 393:1937-1947. 2019
- Single Questions for the Screening of Anxiety and Depression in Hemodialysis. Canadian Journal of Kidney Health and Disease. 6:205435811882544-205435811882544. 2019
- Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. American Society of Nephrology. Clinical Journal. 12:965-973. 2017
- Attitudes and Opinions of Canadian Nephrologists Toward Continuous Quality Improvement Options. Canadian Journal of Kidney Health and Disease. 4:205435811772529-205435811772529. 2017
- The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases. 68:591-598. 2016
- The Safety of Eplerenone in Hemodialysis Patients. American Society of Nephrology. Clinical Journal. 10:1602-1608. 2015
- The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. American Society of Nephrology. Clinical Journal. 10:791-799. 2015
- Coronary Artery Calcification, Cardiovascular Events, and Death: A Prospective Cohort Study of Incident Patients on Hemodialysis. Canadian Journal of Kidney Health and Disease. 2:65-65. 2015
- Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Medicine. 39:2135-2143. 2013
- Adjudication of bleeding outcomes in an international thromboprophylaxis trial in critical illness. Thrombosis Research. 131:204-209. 2013
- Red blood cell transfusion and increased length of storage are not associated with deep vein thrombosis in medical and surgical critically ill patients: a prospective observational cohort study. Critical Care. 15:R263-R263. 2011
- Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. Nephrology Dialysis Transplantation. 25:4002-4009. 2010
- Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal. 160:785-794.e10. 2010
- The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. Journal of Critical Care. 25:287-293. 2010
- Event adjudication and data monitoring in an intensive care unit observational study of thromboprophylaxis. Journal of Critical Care. 24:168-175. 2009
- Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin Dalteparin<subtitle>An Assessment of Safety and Pharmacodynamics: The DIRECT Study</subtitle>. JAMA Internal Medicine. 168:1805-1805. 2008
- Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin prophylaxis: prevalence, incidence and risk factors. Critical Care. 12:R32-R32. 2008
- Review: A low-protein diet delays end-stage renal disease or death in stage 3 to 5 chronic kidney disease. ACP journal club. 145:64-64. 2006
- Meta-Analysis. Journal of the American Society of Nephrology. 17:2591-2598. 2006
- Chronic Kidney Disease and Mortality Risk. Journal of the American Society of Nephrology. 17:2034-2047. 2006
- Thromboembolism and anticoagulant management in hemodialysis patients: A practical guide to clinical management. Thrombosis Research. 118:385-395. 2006
- Anticoagulant prophylaxis in special populations with an indwelling epidural catheter or renal insufficiency. Journal of Critical Care. 20:324-329. 2005
- Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. Journal of Critical Care. 20:357-363. 2005
- Deep venous thrombosis: clinically silent in the intensive care unit. Journal of Critical Care. 20:334-340. 2005
- Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. Journal of Critical Care. 20:364-372. 2005
- Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Journal of Critical Care. 20:348-353. 2005
- Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. Critical Care Medicine. 33:1565-1571. 2005
- Benefit of continuous renal replacement therapy in subgroups of acutely ill patients: a retrospective analysis. Clinical Nephrology. 63:267-275. 2005
- Neither baseline tests of molecular hypercoagulability nor D-dimer levels predict deep venous thrombosis in critically ill medical-surgical patients. Intensive Care Medicine. 31:48-55. 2005
- Protocolized Anemia Management with Erythropoietin in Hemodialysis Patients. Journal of the American Society of Nephrology. 14:2654-2661. 2003
- Prognostic Value of Myocardial Perfusion Studies in Patients with End-Stage Renal Disease Assessed for Kidney or Kidney-Pancreas Transplantation. Journal of the American Society of Nephrology. 14:431-439. 2003
- Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: A meta-analysis. Journal of the American Society of Nephrology. 14:431-439. 2003
- Utility of ultrasonographic venous assessment prior to forearm arteriovenous fistula creation. Clinical Nephrology. 58:122-127. 2002
- Irbesartan was renoprotective in patients with type 2 diabetes, hypertension, and microalbuminuria. ACP journal club. 136:82-82. 2002
- Losartan was renoprotective in diabetic nephropathy independent of its effect on blood pressure. BMJ Evidence-Based Medicine. 7:82-82. 2002
- Irbesartan reduced progression of nephropathy caused by type 2 diabetes independent of the effect on blood pressure.. ACP journal club. 136:82-84. 2002
- The Clinical Utility of Doppler Ultrasound Prior to Arteriovenous Fistula Creation. Seminars in Dialysis. 14:314-317. 2001
- Comparison of Mortality Risk for Dialysis Patients and Cadaveric First Renal Transplant Recipients in Ontario, Canada. Journal of the American Society of Nephrology. 11:917-922. 2000
- Peritoneal Membrane Transport and Hypoalbuminemia: Cause or Effect?. Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 20:14-18. 2000